Shares of Neoprobe Corp. (NYSE Amex:NEOP) continued their strong performance of recent weeks, rising by as much as 8 percent in early Friday trading after the company published results from a phase 2 clinical trial of its cancer-targeting agent.
The gains tapered to an overall loss for the trading day, but NEOP shares were again on the rise in after hours trading. By 5 P.M., the stock was priced at $4.59, up about 7 percent from the day’s close.